ACRO Accreditation Again Receives ISO:9001 2015 Certification

By ACRO
Press Release
Article

ACRO's Accreditation Program has completed and passed its annual surveillance by the International Standards Organization.

ACRO Accreditation is the only U.S. radiation oncology accrediting body to acieve ISO 9001:2015 Certification.

ACRO Accreditation is the only U.S. radiation oncology accrediting body to acieve ISO 9001:2015 Certification.

The American College of Radiation Oncology’s Accreditation Program has completed and passed its annual surveillance by the International Standards Organization (ISO). ACRO Accreditation is the only U.S. radiation oncology accrediting body to achieve ISO 9001:2015 Certification.

The ISO is a highly regarded international certification body which evaluates an organization’s processes and procedures. The program undergoes a comprehensive yearly review of its quality objectives, operations, and structure.

Click here to learn more.

Recent Videos
Although 1 of 21 patients with liver-dominant NETs died due to RILD in the phase 1 study, no RILD-induced deaths were observed in the phase 2 trial.
A simulation procedure helped to ascertain chemotherapy tolerability before administering radioembolization therapy for NETs with liver metastases.
The addition of radioembolization to radiosensitizing chemotherapy may help concurrently treat patients with liver tumors and disease outside the liver.
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
According to Eyub Akdemir, MD, reducing EDIC may be feasible without compromising target coverage to reduce anticipated lymphopenia rates.
A new partnership agreement involving AI use may help spread radiotherapeutic standards from academic centers to more patients in community-based practices.
Recent findings presented at ASTRO 2025 suggest an “exciting opportunity” to expand the role of radiation oncology in different non-malignant indications.
The 3 most likely directions of radiotherapy advancements come from new technology, combinations with immunotherapy, and the incorporation of particle therapy.
Distance and training represent 2 major obstacles to making radiotherapy available to more patients with cancer across the world.
Louis Potters, MD, FASTRO, FABS, FACR, describes how evidence-based radiation protocols may integrate with novel artificial intelligence software.
Related Content